Article Text

Download PDFPDF

451 Patient characteristics and treatment patterns by BRCA/ATM mutation status in ovarian cancer patients: an EHR analysis in the PRIOR-2 study
  1. G Adeboyeje1,
  2. M Sierra2,
  3. A Bartels2,
  4. M Field2,
  5. S Jhamb3,
  6. A Buikema3 and
  7. S Joo4
  1. 1Merck and Co., Inc., MRL, Center for Observational and Real-World Evidence (CORE), Oncology, Kenilworth, USA
  2. 2Optum, Commercial Analytics, Eden Prairie, USA
  3. 3Optum, Health Economics and Outcomes Research, Eden Prairie, USA
  4. 4Merck and Co., Inc., MRL, Center for Observational and Real-World Evidence (CORE), Oncology, North Wales, USA


Introduction/Background*Previous studies have reported median progression-free survival (PFS) of 12-18 months in ovarian cancer (OC). Testing for BRCA1/2 or ATM gene mutations in OC can inform treatment choice. Data on the treatment experience of patients with OC by BRCA/ATM mutational status in the United States (US) is needed.

Methodology We identified female adults, ≥18 years, with OC from Optum’s de-identified electronic health record (EHR) database (1/1/2017 – 6/30/2020; N=16.6M female lives). Index date was first diagnosis of OC. Patients were observed for 12-months pre-index to capture baseline demographic, clinical and prognostic characteristics. Treatment with platinum-taxane CT, PARPi, bevacizumab and transition rates through lines of therapy or death by BRCA/ATM mutational status was examined.

Result(s)*Among 1,901 OC patients tested for BRCA/ATM gene mutation, 616 (32.4%) were positive, 682 (35.9%) were negative and 603 (31.7%) had unknown status. Mean (SD) age was 59.5 (10.9) and 62.2 (12.1) years for patients with BRCA/ATM mutation and no mutation. No meaningful differences by BRCA/ATM mutational status (yes vs no) were found in the proportion of patients with stage 3/4 cancer (52.1% vs 52.1%), visceral metastasis (35.9% vs 31.8%) or ascites (30.8% vs 30.2%), at presentation; or in 1L platinum-taxane CT initiation (55% at 6 months). PARPi use differed by BRCA/ATM status and increased over time (table 1).

Abstract 451 Table 1

Treatments received and transition rates through lines of therapy or death

Conclusion*While there are few differences in characteristics between patients by BRCA/ATM status, PARPi use was higher in patients with BRCA/ATM mutation; patients with no BRCA/ATM mutation were more often treated with bevacizumab. There is need for further research to understand the role of BRCA/ATM status on treatment choice and outcomes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.